Placebo News and Research

RSS

Menopause symptoms return with a vengence when women stop HRT

In somewhat depressing news for women battling that often miserable phase in their lives, the menopause, it appears that more than half of women who start taking hormone replacement therapy to relieve the discomfort, can expect to see a dramatic resurgence of those symptoms, when they discontinue the therapy.

12 Jul 2005

Nitric oxide good for some prem babies but not for others

According to two new studies, although nitric oxide can halve the risk of developmental problems in premature babies with undeveloped lungs, the gas could be harmful to newborns who are too small and too ill.

7 Jul 2005

Accuracy of PSA screening for detecting prostate cancer

A new study indicates there is no specific PSA value that has both high sensitivity and high specificity for monitoring healthy men for prostate cancer, but rather there is a continuum of prostate cancer risk at all values of PSA, according to a study in the July 6 issue of JAMA: The Journal of the American Medical Association.

6 Jul 2005

Novel inhibitor offsets neurotoxic effects of tPA - possible new stroke treatments

A research team lead by the Burnham Institute has synthesized and tested a new series of inhibitors that can prevent the type of nerve cell injury and death associated with many neurodegenerative diseases and stroke.

6 Jul 2005

Vitamin E fails to deliver benefits for major cardiovascular events or cancer

In an article in the July 6 JAMA, I-Min Lee, M.B.B.S., Sc.D., of Brigham and Women's Hospital and Harvard Medical School, Boston, and colleagues analyzed data from the vitamin E component of the Women's Health Study, which tested whether vitamin E supplementation decreases the risk of cardiovascular disease and cancer among healthy women.

6 Jul 2005

Aspirin can help prevent heart disease, but vitamin E no protection against cancer

It may have taken 12 years, but researchers now say that studies involving nearly 40,000 women in the U.S. has found that regular, low doses of aspirin do not prevent cancer, and vitamin E is pretty ineffective in warding off both heart disease and cancer.

6 Jul 2005

Drug therapy may be effective in treating both the manic and depressive phases of bipolar disorder

The condition (bipolar I and II) affects approximately 8 million Americans, who have relied on a combination of drugs to manage their symptoms, and who remain at high risk of committing suicide because of the difficulty in treating the disorder.

6 Jul 2005

Orthodontics takes first step toward biological control of tooth movement

In the first study of its kind, University of Florida researchers are testing the power of a natural human hormone to biochemically move teeth faster and less painfully during orthodontic treatment.

6 Jul 2005

Vitamin E supplements do not protect healthy women against heart attacks and stroke

Vitamin E supplements do not protect healthy women against heart attacks and stroke, according to new results from the Women's Health Study, a long-term clinical trial of the effect of vitamin E and aspirin on both the prevention of cardiovascular disease and of cancer.

5 Jul 2005

Bone Medical completes first trial of oral parathyroid hormone product for treatment of osteoporosis

Bone Medical Ltd announced today the completion of a Phase I trial of its oral parathyroid hormone (PTH) product Perthoxal™ under development for the treatment of osteoporosis.

3 Jul 2005

Daclizumab effective at reducing organ rejection and risk of infection in heart transplant patients

A new study shows that a drug, called daclizumab, is effective at reducing organ rejection and risk of infection in heart transplant patients. The multi-center study by cardiologists from the United States, Sweden, Germany and Canada will be published in the June 30 issue of The New England Journal of Medicine.

30 Jun 2005

Bipolar survey indicates how patient satisfaction is achieved

Preliminary results from a large-scale global study of people living with bipolar disorder, presented today at the World Congress of Biological Psychiatry (WCBP), found that patient satisfaction with treatment is achieved through combining broad-based efficacy with a favourable tolerability profile.

30 Jun 2005

Myriad Genetics issued new patent under license

Myriad Genetics has announced the issuance of Patent No. 6,911,466 entitled, "AB42 Lowering Agents". Myriad holds exclusive rights to the patent under a licensing agreement with Mayo Clinic. The patent covers methods of using a broad class of compounds known as selective amyloid beta 42 lowering agents (SALAs) to lower levels of the toxic peptide.

29 Jun 2005

Experimental drug for diabetes looks promising

Encouraging results in a small study, with a new experimental treatment, promises help for certain diabetics to retain some ability to make their own insulin.

29 Jun 2005

Tetracycline antibiotic shows promise for treating osteoarthritis

A tetracycline antibiotic, doxycycline, has been successfully used to treat a wide-range of bacterial infections. In addition to its effects as an antibiotic, doxycycline has other actions as a drug and, in laboratory studies with animals and with human tissue, can inhibit the degradation of cartilage in a way that could be useful for the treatment of osteoarthritis (OA).

28 Jun 2005